Regramming myeloid responses to improve cancer immunotherapy

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Zhu, Yu ^a   Hawkins, William G ^a   Denardo, David G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; Immune checkpoints; Macrophages; MDSCs; PD 1

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; PROGRAMMED DEATH 1 RECEPTOR; SIPULEUCEL T;

ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CELL INFILTRATION; CELL MIGRATION; CYTOTOXIC T LYMPHOCYTE; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; MELANOMA; METASTATIC MELANOMA; NUCLEAR REPROGRAMMING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSTATE CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84944463540     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.974399     Document Type: Article

References (10)

1. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PDL1 to reactivate the host immune response against cancer. Br J Cancer 2013; 108:1560-5; PMID:23511566; http://dx. doi.org/10.1038/bjc.2013.117
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
3. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/ nrc2355
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/ 10.1056/NEJMoa1001294
5. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi.org/10.1097/ CJI.0b013e3181eec14c
6. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immuno 2009; 9:162-74; PMID:19197294; http://dx. doi.org/10.1038/nri2506
7. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141:39-51; PMID:20371344; http://dx.doi.org/10.1016/j. cell.2010.03.014
8. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, Kaplan RN, Mackall CL. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Translat Med 2014; 6:237ra67; PMID:24848257; http://dx.doi.org/10.1126/scitranslmed. 3007974
9. Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res 2014; 74(18):5057-69; PMID:25085815; http://dx.doi.org/10.1158/0008-5472.CAN-13-3723
10. Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber TG, West BL, Bollag G, Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res 2014; 74:153-61; PMID:24247719; http://dx.doi.org/ 10.1158/0008-5472.CAN-13-1816